Key result
SLE is linked to ~13% higher non-calcified coronary plaque burden versus controls.
Why the study?
Subjects with SLE have an enhanced risk of atherosclerotic CVD not explained by Framingham risk, prompting evaluation of NMR spectroscopy measurements of lipoprotein particles and GlycA to predict coronary atherosclerosis.
Does Systemic Lupus Erythematosus and its associated proatherogenic lipoprotein profile increase coronary plaque burden compared to healthy controls?
Cross-Sectional (n=94)
No
Does Systemic Lupus Erythematosus and its associated proatherogenic lipoprotein profile increase coronary plaque burden compared to healthy controls?
NMR measures of GlycA and lipoprotein profiles may help assess cardiovascular risk and subclinical coronary artery disease in patients with SLE beyond routine clinical labs.
Answers are grounded in this paper and cite their sources.
Supports advanced lipoprotein profiling for SLE CV risk assessment; hypothesis-generating and requires longitudinal validation before practice change.
OBJECTIVE: Subjects with SLE display an enhanced risk of atherosclerotic cardiovascular disease (CVD) that is not explained by Framingham risk. This study sought to investigate the utility of nuclear MR (NMR) spectroscopy measurements of serum lipoprotein particle counts and size and glycoprotein acetylation (GlycA) burden to predict coronary atherosclerosis in SLE. METHODS: Coronary plaque burden was assessed in SLE subjects and healthy controls using coronary CT angiography. Lipoproteins and GlycA were quantified by NMR spectroscopy. RESULTS: SLE subjects displayed statistically significant decreases in high-density lipoprotein (HDL) particle counts and increased very low-density lipoprotein (VLDL) particle counts compared with controls. Non-calcified coronary plaque burden (NCB) negatively associated with HDL subsets whereas it positively associated with VLDL particle counts in multivariate adjusted models. GlycA was significantly increased in SLE sera compared with controls. In contrast to high-sensitivity C reactive protein, elevations in GlycA in SLE significantly associated with NCB and insulin resistance (IR), though the association with NCB was no longer significant after adjusting for prednisone use. CONCLUSIONS: Patients with SLE display a proatherogenic lipoprotein profile that may significantly contribute to the development of premature CVD. The results demonstrate that NMR measures of GlycA and lipoprotein profiles, beyond what is captured in routine clinical labs, could be a useful tool in assessing CVD risk in patients with SLE.
No takes yet. Share an insight, caveat, or question.
Purmalek et al. (2019) conducted a cross-sectional in Systemic Lupus Erythematosus (SLE) (n=94). Systemic Lupus Erythematosus (SLE) vs. Healthy controls was evaluated on Non-calcified coronary plaque burden (NCB) (p=<0.001). SLE subjects had significantly elevated non-calcified coronary plaque burden compared to controls (86 vs 76 mm2, p<0.001), which associated with proatherogenic lipoprotein subfractions.
Synapse has enriched 10 related papers. Consider them for comparative context: